Sodium-glucose cotransporter-2 inhibitors are not recommended for T3cDM until their safety is confirmed with regard to the risk of euglycemic diabetic ketoacidosis in insulin-deficient states [14, 21]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.